Intrinsic value of BioCryst Pharmaceuticals - BCRX

Previous Close

$4.38

  Intrinsic Value

$9.47

stock screener

  Rating & Target

str. buy

+116%

  Value-price divergence*

0%

Previous close

$4.38

 
Intrinsic value

$9.47

 
Up/down potential

+116%

 
Rating

str. buy

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of BCRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -45.83
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  26
  42
  64
  96
  139
  197
  271
  363
  477
  613
  775
  962
  1,176
  1,418
  1,687
  1,984
  2,308
  2,658
  3,035
  3,437
  3,864
  4,316
  4,791
  5,291
  5,813
  6,359
  6,928
  7,520
  8,137
  8,778
  9,444
Variable operating expenses, $m
 
  24
  37
  55
  80
  114
  156
  210
  275
  354
  447
  555
  679
  818
  973
  1,145
  1,331
  1,534
  1,751
  1,983
  2,230
  2,490
  2,765
  3,053
  3,354
  3,669
  3,997
  4,339
  4,695
  5,065
  5,449
Fixed operating expenses, $m
 
  64
  65
  67
  68
  70
  72
  74
  76
  77
  79
  81
  83
  85
  88
  90
  92
  94
  97
  99
  102
  104
  107
  109
  112
  115
  118
  121
  124
  127
  130
Total operating expenses, $m
  75
  88
  102
  122
  148
  184
  228
  284
  351
  431
  526
  636
  762
  903
  1,061
  1,235
  1,423
  1,628
  1,848
  2,082
  2,332
  2,594
  2,872
  3,162
  3,466
  3,784
  4,115
  4,460
  4,819
  5,192
  5,579
Operating income, $m
  -49
  -46
  -38
  -26
  -9
  13
  43
  80
  126
  182
  248
  326
  414
  514
  626
  749
  884
  1,030
  1,187
  1,355
  1,533
  1,722
  1,920
  2,129
  2,347
  2,575
  2,813
  3,060
  3,318
  3,586
  3,865
EBITDA, $m
  -49
  -45
  -37
  -24
  -7
  17
  48
  87
  135
  194
  263
  344
  437
  542
  658
  787
  928
  1,081
  1,245
  1,421
  1,607
  1,804
  2,012
  2,230
  2,458
  2,697
  2,946
  3,205
  3,474
  3,755
  4,046
Interest expense (income), $m
  0
  2
  3
  6
  9
  14
  20
  28
  38
  51
  66
  83
  104
  127
  153
  183
  215
  250
  289
  330
  373
  420
  469
  521
  575
  632
  692
  754
  818
  886
  956
Earnings before tax, $m
  -55
  -48
  -41
  -32
  -19
  -1
  22
  52
  88
  131
  183
  242
  311
  387
  473
  567
  669
  780
  899
  1,025
  1,160
  1,302
  1,451
  1,607
  1,771
  1,942
  2,121
  2,306
  2,500
  2,700
  2,909
Tax expense, $m
  0
  0
  0
  0
  0
  0
  6
  14
  24
  35
  49
  65
  84
  105
  128
  153
  181
  211
  243
  277
  313
  351
  392
  434
  478
  524
  573
  623
  675
  729
  785
Net income, $m
  -55
  -48
  -41
  -32
  -19
  -1
  16
  38
  64
  96
  133
  177
  227
  283
  345
  414
  488
  569
  656
  748
  846
  950
  1,059
  1,173
  1,293
  1,418
  1,548
  1,684
  1,825
  1,971
  2,124

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  55
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  90
  144
  222
  333
  483
  681
  936
  1,256
  1,650
  2,123
  2,681
  3,329
  4,071
  4,906
  5,838
  6,864
  7,985
  9,198
  10,501
  11,893
  13,371
  14,934
  16,580
  18,306
  20,114
  22,002
  23,971
  26,022
  28,155
  30,373
  32,679
Adjusted assets (=assets-cash), $m
  35
  144
  222
  333
  483
  681
  936
  1,256
  1,650
  2,123
  2,681
  3,329
  4,071
  4,906
  5,838
  6,864
  7,985
  9,198
  10,501
  11,893
  13,371
  14,934
  16,580
  18,306
  20,114
  22,002
  23,971
  26,022
  28,155
  30,373
  32,679
Revenue / Adjusted assets
  0.743
  0.292
  0.288
  0.288
  0.288
  0.289
  0.290
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
  0.289
Average production assets, $m
  5
  8
  12
  18
  27
  38
  52
  70
  92
  118
  149
  185
  226
  272
  324
  381
  443
  510
  583
  660
  742
  829
  920
  1,016
  1,116
  1,221
  1,330
  1,444
  1,562
  1,685
  1,813
Working capital, $m
  13
  -4
  -6
  -10
  -14
  -20
  -27
  -36
  -48
  -61
  -77
  -96
  -118
  -142
  -169
  -198
  -231
  -266
  -303
  -344
  -386
  -432
  -479
  -529
  -581
  -636
  -693
  -752
  -814
  -878
  -944
Total debt, $m
  54
  96
  166
  265
  400
  579
  808
  1,097
  1,451
  1,876
  2,379
  2,963
  3,630
  4,382
  5,220
  6,144
  7,152
  8,244
  9,417
  10,670
  12,000
  13,407
  14,888
  16,442
  18,069
  19,768
  21,540
  23,385
  25,305
  27,302
  29,377
Total liabilities, $m
  88
  130
  200
  299
  434
  613
  842
  1,131
  1,485
  1,910
  2,413
  2,997
  3,664
  4,416
  5,254
  6,178
  7,186
  8,278
  9,451
  10,704
  12,034
  13,441
  14,922
  16,476
  18,103
  19,802
  21,574
  23,419
  25,339
  27,336
  29,411
Total equity, $m
  2
  14
  22
  33
  48
  68
  94
  126
  165
  212
  268
  333
  407
  491
  584
  686
  798
  920
  1,050
  1,189
  1,337
  1,493
  1,658
  1,831
  2,011
  2,200
  2,397
  2,602
  2,815
  3,037
  3,268
Total liabilities and equity, $m
  90
  144
  222
  332
  482
  681
  936
  1,257
  1,650
  2,122
  2,681
  3,330
  4,071
  4,907
  5,838
  6,864
  7,984
  9,198
  10,501
  11,893
  13,371
  14,934
  16,580
  18,307
  20,114
  22,002
  23,971
  26,021
  28,154
  30,373
  32,679
Debt-to-equity ratio
  27.000
  6.640
  7.470
  7.980
  8.300
  8.500
  8.640
  8.730
  8.790
  8.840
  8.870
  8.900
  8.920
  8.930
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  -0.714
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -55
  -48
  -41
  -32
  -19
  -1
  16
  38
  64
  96
  133
  177
  227
  283
  345
  414
  488
  569
  656
  748
  846
  950
  1,059
  1,173
  1,293
  1,418
  1,548
  1,684
  1,825
  1,971
  2,124
Depreciation, amort., depletion, $m
  0
  1
  1
  2
  3
  4
  5
  7
  9
  12
  15
  18
  23
  27
  32
  38
  44
  51
  58
  66
  74
  83
  92
  102
  112
  122
  133
  144
  156
  169
  181
Funds from operations, $m
  -60
  -47
  -40
  -30
  -16
  3
  21
  45
  73
  108
  148
  195
  249
  310
  377
  452
  533
  620
  714
  814
  921
  1,033
  1,151
  1,275
  1,405
  1,540
  1,681
  1,828
  1,981
  2,140
  2,305
Change in working capital, $m
  -7
  -2
  -2
  -3
  -4
  -6
  -7
  -9
  -11
  -14
  -16
  -19
  -21
  -24
  -27
  -30
  -32
  -35
  -38
  -40
  -43
  -45
  -48
  -50
  -52
  -55
  -57
  -59
  -62
  -64
  -67
Cash from operations, $m
  -53
  -45
  -38
  -27
  -12
  9
  29
  54
  85
  121
  164
  214
  271
  334
  404
  481
  565
  655
  752
  855
  963
  1,078
  1,199
  1,325
  1,457
  1,595
  1,738
  1,887
  2,043
  2,204
  2,372
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -12
  -15
  -18
  -23
  -27
  -32
  -38
  -44
  -51
  -58
  -66
  -74
  -83
  -92
  -102
  -112
  -122
  -133
  -144
  -156
  -169
New CAPEX, $m
  -5
  -3
  -4
  -6
  -8
  -11
  -14
  -18
  -22
  -26
  -31
  -36
  -41
  -46
  -52
  -57
  -62
  -67
  -72
  -77
  -82
  -87
  -91
  -96
  -100
  -105
  -109
  -114
  -118
  -123
  -128
Cash from investing activities, $m
  23
  -4
  -5
  -7
  -10
  -14
  -18
  -23
  -29
  -35
  -43
  -51
  -59
  -69
  -79
  -89
  -100
  -111
  -123
  -135
  -148
  -161
  -174
  -188
  -202
  -217
  -231
  -247
  -262
  -279
  -297
Free cash flow, $m
  -30
  -49
  -43
  -34
  -22
  -5
  11
  31
  56
  86
  122
  163
  211
  265
  325
  392
  465
  544
  628
  719
  815
  917
  1,024
  1,137
  1,255
  1,378
  1,507
  1,641
  1,780
  1,925
  2,075
Issuance/(repayment) of debt, $m
  0
  42
  71
  99
  135
  178
  230
  288
  354
  426
  503
  583
  667
  752
  838
  924
  1,008
  1,092
  1,173
  1,253
  1,330
  1,406
  1,481
  1,554
  1,627
  1,699
  1,772
  1,845
  1,920
  1,996
  2,075
Issuance/(repurchase) of shares, $m
  0
  60
  49
  43
  34
  21
  9
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  23
  102
  120
  142
  169
  199
  239
  288
  354
  426
  503
  583
  667
  752
  838
  924
  1,008
  1,092
  1,173
  1,253
  1,330
  1,406
  1,481
  1,554
  1,627
  1,699
  1,772
  1,845
  1,920
  1,996
  2,075
Total cash flow (excl. dividends), $m
  -7
  53
  77
  108
  147
  194
  250
  319
  410
  512
  624
  747
  878
  1,017
  1,164
  1,316
  1,473
  1,635
  1,802
  1,972
  2,146
  2,324
  2,505
  2,691
  2,882
  3,078
  3,279
  3,486
  3,700
  3,921
  4,150
Retained Cash Flow (-), $m
  46
  -60
  -49
  -43
  -34
  -21
  -26
  -32
  -39
  -47
  -56
  -65
  -74
  -84
  -93
  -103
  -112
  -121
  -130
  -139
  -148
  -156
  -165
  -173
  -181
  -189
  -197
  -205
  -213
  -222
  -231
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -7
  28
  65
  113
  173
  224
  287
  370
  464
  568
  682
  804
  934
  1,070
  1,213
  1,361
  1,514
  1,671
  1,833
  1,998
  2,167
  2,341
  2,519
  2,701
  2,889
  3,082
  3,281
  3,486
  3,699
  3,920
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  -7
  25
  57
  93
  134
  163
  194
  232
  267
  298
  324
  343
  355
  359
  356
  346
  329
  308
  282
  254
  224
  194
  165
  138
  112
  90
  70
  54
  40
  30
Current shareholders' claim on cash, %
  100
  24.9
  18.6
  15.6
  14.1
  13.6
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4
  13.4

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, an oral serine protease inhibitor, which is in Phase II clinical trial for HAE; and other second generation HAE compounds, an oral serine protease inhibitor, which is in preclinical stage. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in preparation to file for regulatory approval. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; and Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

FINANCIAL RATIOS  of  BioCryst Pharmaceuticals (BCRX)

Valuation Ratios
P/E Ratio -5.9
Price to Sales 12.4
Price to Book 161.6
Price to Tangible Book
Price to Cash Flow -6.1
Price to Free Cash Flow -5.6
Growth Rates
Sales Growth Rate -45.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 1300%
Total Debt to Equity 2700%
Interest Coverage 0
Management Effectiveness
Return On Assets -51.9%
Ret/ On Assets - 3 Yr. Avg. -44.5%
Return On Total Capital -82.1%
Ret/ On T. Cap. - 3 Yr. Avg. -65.2%
Return On Equity -220%
Return On Equity - 3 Yr. Avg. -136.5%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 92.3%
Gross Margin - 3 Yr. Avg. 96.7%
EBITDA Margin -211.5%
EBITDA Margin - 3 Yr. Avg. -207.5%
Operating Margin -188.5%
Oper. Margin - 3 Yr. Avg. -197.7%
Pre-Tax Margin -211.5%
Pre-Tax Margin - 3 Yr. Avg. -207.5%
Net Profit Margin -211.5%
Net Profit Margin - 3 Yr. Avg. -207.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

BCRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BCRX stock intrinsic value calculation we used $26 million for the last fiscal year's total revenue generated by BioCryst Pharmaceuticals. The default revenue input number comes from 2016 income statement of BioCryst Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BCRX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BCRX is calculated based on our internal credit rating of BioCryst Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of BioCryst Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BCRX stock the variable cost ratio is equal to 57.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $62 million in the base year in the intrinsic value calculation for BCRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for BioCryst Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for BioCryst Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BCRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BCRX are equal to 19.2%.

Life of production assets of 10 years is the average useful life of capital assets used in BioCryst Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BCRX is equal to -10%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2 million for BioCryst Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 83.531 million for BioCryst Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of BioCryst Pharmaceuticals at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
GILD Gilead Science 73.34 173.49  str.buy
AVIR Aviragen Thera 0.580 0.30  sell
ACHN Achillion Phar 4.82 0.89  str.sell
NVAX Novavax 1.000 0.06  str.sell
VICL Vical 2.37 1.05  str.sell

COMPANY NEWS

▶ BioCryst reports 2Q loss   [Aug-07-17 11:57PM  Associated Press]
▶ Down 24.6%, is BioCryst Pharmaceuticals Stock Now a Buy?   [Jun-06-17 12:03PM  Motley Fool]
▶ Flu therapy from RTP's BioCryst could be available for kids next season   [11:05AM  American City Business Journals]
▶ BioCryst Announces RAPIVAB® Pediatric sNDA Acceptance   [Jun-05-17 06:00AM  GlobeNewswire]
▶ Why BioCryst Pharmaceuticals Stock Caught Fire Today   [May-25-17 03:06PM  Motley Fool]
▶ Stocks rise for Aerie, BioCryst following positive trial results   [02:55PM  American City Business Journals]
▶ BioCryst reports 1Q loss   [06:20AM  Associated Press]
▶ After announcing a $45M public offering, BioCryst to launch new trial   [Apr-13-17 12:13PM  American City Business Journals]
▶ BioCryst to receive royalties from cancer treatment approved in Japan   [Apr-04-17 10:50AM  American City Business Journals]
▶ Wait for the Pullback on BioCryst Pharmaceuticals   [Mar-20-17 01:29PM  TheStreet.com]
▶ Don't Let Offerings Blindside Your Thesis   [Mar-19-17 01:51PM  Benzinga]
▶ BioCryst Pharmaceuticals, Inc. (BCRX): A Discount Entry?   [Mar-01-17 09:40AM  at Insider Monkey]
▶ BioCryst 4Q Net 6 Cents a Share Beats Street   [12:25PM  at Investopedia]
▶ BioCryst plans for European launch of injectable flu therapy   [Jan-30-17 02:55PM  at bizjournals.com]
Stock chart of BCRX Financial statements of BCRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.